Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Mar. 31, 2018
Current assets:    
Cash and cash equivalents $ 12,910 $ 17,583
Short-term investments 39,119 43,968
Research and development incentives receivable 2,251 2,389
Prepaid expenses and other current assets 944 763
Total current assets 55,224 64,703
Property, plant and equipment, net 443 370
Deferred offering costs 1,344  
Research and development incentives receivable - long term 426  
Restricted cash 1,856 78
Total assets 59,293 65,151
Current liabilities:    
Accounts payable 2,854 1,993
Accrued expenses and other current liabilities 1,642 3,171
Total current liabilities 4,496 5,164
Deferred rent, net of current portion 43 52
Warrant liability 7,092 1,642
Total liabilities 11,631 6,858
Commitments and contingencies (Note 13)
Convertible preferred stock (Series Seed, A and B), $0.001 par value; 1,975,968 shares authorized as of June 30, 2018 and March 31, 2018; 1,925,968 shares issued and outstanding as of June 30, 2018 and March 31, 2018 86,361 86,361
Stockholders' Deficit:    
Common stock, $0.001 par value; 27,314,288 shares authorized (inclusive of 26,258 shares of common A stock) as of June 30, 2018 and March 31, 2018; 5,007,485 shares issued and outstanding (inclusive of 26,258 shares of common A stock) as of June 30, 2018 and March 31, 2018 5 5
Additional paid-in capital 1,322 1,097
Accumulated deficit (38,976) (28,932)
Accumulated other comprehensive loss (1,050) (238)
Total stockholders' deficit (38,699) (28,068)
Total liabilities, convertible preferred stock and stockholders' deficit $ 59,293 $ 65,151